A LipiDiDiet trial investigated the effects of Fortasyn Connect on cognitive decline (and related measures) in the early stages of Alzheimer’s Disease. This small trial indicates that Nutricia’s nutrient drink Souvenaid has no significant effect on the rate of decline in cognitive performance during prodromal Alzheimer’s Disease, as measured using neuropsychological test battery scores, over 2-years.
Certain aspects of brain deterioration may have been lower than expected, however, so further larger trials may be required to assess the effectiveness of this intervention conclusively.
“The treatment did not appear to offer an advantage, although patients in the Souvenaid group did have slightly less brain shrinkage on scans, which the researchers say is promising because shrinkage in brain regions controlling memory is seen with worsening dementia”.
Alzheimer’s nutrient drink falters in clinical trial. London: BBC Health News, October 31st 2017.
This relates to:
Soininen, H. Solomon, A. [and] Visser, PJ. [et al] (2017). 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. The Lancet Neurology.
Further coverage of the above research:
Nutrient drink for Alzheimer’s has disappointing result in trial. London: NHS Choices; Behind the Headlines, October 31st 2017.
A separate ongoing trial:
Scheltens, NME. Kuyper, IS. [and] Boellaard, R. [et al] (2016). Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer’s disease. Alzheimers & Dementia. September 1st 2016; 2(4): 233-240.